Article
Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research - 16 Mar 2026
Pant Shubham, Park Joon Oh, Su Wu-Chou, Loriot Yohann, Carranza Omar, Corassa Marcelo, Doi Toshihiko, Qin Shukui, Tabernero Josep, Prenen Hans, Folprecht Gunnar, Winter Helen, Dal Molin Graziela Z, Shen Lin, Qian Jiaqi, Liao Huimin, Thomas Shibu, Sweiti Hussein, Triantos Spyros, Feng Yin-Hsun
Abstract excerpt
PURPOSE: Up to 20% of patients with cholangiocarcinoma (CCA) harbor FGFR gene aberrations. Erdafitinib is approved for pretreated, locally advanced/metastatic urothelial carcinoma with susceptible FGFR3 alterations. The present study evaluated the efficacy and safety of erdafitinib using a pooled analysis of patients with CCA from the RAGNAR and LUC2001 studies. EXPERIMENTAL DESIGN: In RAGNAR (phase II, global,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.